Baylor Institute for Immunology Research, Dallas, TX, USA.
NeuroMedical Center Clinic, Baton Rouge, LA, USA.
Neurol Ther. 2015 Dec;4(2):137-46. doi: 10.1007/s40120-015-0037-x. Epub 2015 Nov 2.
Delayed-release dimethyl fumarate (DMF, also known as gastro-resistant DMF) is indicated for the treatment of patients with relapsing multiple sclerosis. Gastrointestinal (GI) adverse events (AEs) occur with DMF therapy.
We used a Delphi process to reach consensus among North American clinicians on effective real-world management strategies for GI AEs associated with DMF. Clinicians were asked to complete two rounds of questionnaires developed by a steering committee; consensus in round 2 was attained if ≥70% of respondents agreed on a particular strategy.
Consensus was reached on several strategies to manage GI AEs, including administering DMF with food, slow titration, dose reduction, and use of symptomatic therapies.
These consensus strategies provide clinicians with information on real-world approaches used to address the tolerability of DMF in patients with multiple sclerosis.
Biogen.
延迟释放富马酸二甲酯（DMF，也称为耐胃酸 DMF）用于治疗复发型多发性硬化症患者。DMF 治疗会引起胃肠道（GI）不良反应（AE）。
我们使用 Delphi 流程在北美临床医生中就与 DMF 相关的 GI AE 的有效真实世界管理策略达成共识。临床医生被要求完成由指导委员会制定的两轮问卷；如果≥70%的应答者同意特定策略，则在第二轮中达成共识。
针对管理 GI AE 的几种策略达成了共识，包括随餐服用 DMF、缓慢滴定、剂量减少和使用对症治疗。
这些共识策略为临床医生提供了有关用于解决多发性硬化症患者 DMF 耐受性的真实世界方法的信息。
Biogen。
